Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C. Baldini

Feasibility and Benefit of Molecularly-Informed Enrollment Into Early Phase Clinical Trials for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

FRI0352 Damage Accrual in a Large Monocentric Cohort of Primary sjÖgren’s Syndrome Patients: Determinants and Impact on Patient Reported Outcomes

2018

English

Related publications

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

English

Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma

Current Oncology

Oncology

2019

English

Phase 2 Study of Parsaclisib (Incb050465) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Citadel-202)

Hematological Oncology

English

Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma

American Journal of Hematology

Hematology

2019

English

A Phase Iia Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy

Clinical Lymphoma, Myeloma and Leukemia

English

Bone Marrow Molecular Markers Associated With Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma

BioMed Research International

English

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Pcn177 - Cost-Effectiveness of Tisagenlecleucel for Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma : A Canadian Societal Perspective

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C. Baldini

Feasibility and Benefit of Molecularly-Informed Enrollment Into Early Phase Clinical Trials for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

FRI0352 Damage Accrual in a Large Monocentric Cohort of Primary sjÖgren’s Syndrome Patients: Determinants and Impact on Patient Reported Outcomes

Related publications

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma

Phase 2 Study of Parsaclisib (Incb050465) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Citadel-202)

Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma

A Phase Iia Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy

Bone Marrow Molecular Markers Associated With Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Pcn177 - Cost-Effectiveness of Tisagenlecleucel for Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma : A Canadian Societal Perspective